Advertisement

Cambridge-based cancer pharmaceutical company Millennium: The Takeda Oncology Company and parent Takeda Pharmaceutical Co. Ltd. of Osaka, Japan, said they have submitted two supplemental new drug applications (NDAs) for Velcade, a cancer treatment, to the U.S. Food and Drug Administration.

The first supplemental NDA seeks to add a subcutaneous route of administration for the drug, and the second is for Velcade in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma. The drug currently is approved for intravenous use in patients with multiple myeloma and those with mantle cell lymphoma.

SOURCE

Advertisement
Advertisement